Initial attempts at clinical translation of PARP inhibition relied on a strategy of synthetic lethality targeting genetically vulnerable tumors such as BRCA1- and BRCA2-deficient breast and ovarian cancers. This evidence concerns the gene BRCA2 and ovarian carcinoma.